首页> 外文期刊>Seminars in cancer biology >AGC kinases, mechanisms of regulation and innovative drug development
【24h】

AGC kinases, mechanisms of regulation and innovative drug development

机译:AGC激酶,调节机制和创新药物开发机制

获取原文
获取原文并翻译 | 示例
       

摘要

The group of AGC kinases consists of 63 evolutionarily related serine/threonine protein kinases comprising PDK1, PKB/Akt, SGK, PKC, PRK/PKN, MSK, RSK, S6K, PKA, PKG, DMPK, MRCK, ROCK, NDR, LATS, CRIK, MAST, GRK, Sgk494, and YANK, while two other families, Aurora and PLK, are the most closely related to the group. Eight of these families are physiologically activated downstream of growth factor signalling, while other AGC kinases are downstream effectors of a wide range of signals. The different AGC kinase families share aspects of their mechanisms of inhibition and activation. In the present review, we update the knowledge of the mechanisms of regulation of different AGC kinases. The conformation of the catalytic domain of many AGC kinases is regulated allosterically through the modulation of the conformation of a regulatory site on the small lobe of the kinase domain, the PIF-pocket. The PIF-pocket acts like an ON-OFF switch in AGC kinases with different modes of regulation, i.e. PDK1, PKB/Akt, LATS and Aurora kinases. In this review, we make emphasis on how the knowledge of the molecular mechanisms of regulation can guide the discovery and development of small allosteric modulators. Molecular probes stabilizing the PIF-pocket in the active conformation are activators, while compounds stabilizing the disrupted site are allosteric inhibitors. One challenge for the rational development of allosteric modulators is the lack of complete structural information of the inhibited forms of full-length AGC kinases. On the other hand, we suggest that the available information derived from molecular biology and biochemical studies can already guide screening strategies for the identification of innovative mode of action molecular probes and the development of selective allosteric drugs for the treatment of human diseases.
机译:AGC激酶组由63种进化相关的丝氨酸/苏氨酸蛋白激酶组成,包含PDK1,PKB / AKT,SGK,PKC,PRK / PKN,MSK,RSK,S6K,PKA,PKG,DMPK,MRCK,ROCK,NDR,LAT, CRIK,MAST,GRK,SGK494和Yank,而另外两家家庭,极光和PLK,是与本集团最密切的。这些家庭中的八个在生长因子信号传导的下游生理上活化,而其他AGC激酶是各种信号的下游效应。不同的AGC激酶家族分享其抑制和激活机制的方面。在本综述中,我们更新了不同AGC激酶的调节机制的知识。许多AGC激酶的催化结构域的构象是通过调节激酶结构域的小叶片上的调节位点的构象来调节,该PIF袋。 PIF袋的作用类似于AGC激酶的开关,具有不同的调节模式,即PDK1,PKB / AKT,LAT和极光激酶。在这篇综述中,我们强调了监管分子机制的知识如何指导小颠振调制器的发现和发展。稳定PIF袋中的分子探针在主动构象中是活化剂,而稳定破坏位点的化合物是变构抑制剂。颠覆调节剂合理发展的一个挑战是缺乏抑制形式的全长AGC激酶的完整结构信息。另一方面,我们建议,来自分子生物学和生物化学研究的可用信息已经可以指导筛查识别创新的作用分子探测模式和用于治疗人类疾病的选择性变构毒性的发展的筛选策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号